EBV相关NK/T细胞淋巴瘤的研究进展  

Research progress on EBV-associated NK/T cell lymphoma

作　　者：蔡君 曹益 邱莉云 高岩[1] 黄慧强[1] 蔡清清[1] CAI Jun;CAO Yi;QIU LiYun;GAO Yan;HUANG HuiQiang;CAI QingQing(State Key Laboratory of Oncology in South China,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室,广东省鼻咽癌诊治研究重点实验室,广东省恶性肿瘤临床医学研究中心,中山大学肿瘤防治中心,广州510060

出　　处：《中国科学：生命科学》2024年第12期2363-2384,共22页Scientia Sinica(Vitae)

基　　金：国家自然科学基金(批准号:82230001,82270199);广州市科技重点研发计划(批准号:2024B03J1291);国家重点研发计划(批准号:2022YFC2502602);中山大学临床医学研究5010计划(批准号:2020009);北京希思科临床肿瘤学研究基金重点项目(批准号:Y-SY2021ZD-0110)资助。

摘　　要：NK/T细胞淋巴瘤(natural killer/T-cell lymphoma,NKTCL)是一种罕见的且侵袭性高的非霍奇金淋巴瘤亚型,其发病率存在显著的地域差异,高发于亚洲及拉丁美洲,与EB病毒(Epstein-Barr virus,EBV)感染密切相关.近年来,高通量测序技术的应用揭示了NKTCL异质性的生物学基础和发生发展的分子致病机制,包括染色体6q21等位基因缺失引起抑癌基因沉默,EB病毒感染及体细胞基因突变导致多条致癌信号通路异常激活,以及表观遗传学调控异常等.目前针对NKTCL,国内外尚无统一的治疗标准,早期以放疗和化疗综合治疗为主,而晚期以单纯化疗为主.晚期及复发难治性患者的预后较差,亟需探索更多有效的治疗方案,随着全球新药研发加速演进,NKTCL领域各种新药也层出不穷.本文就EBV相关NK/T细胞淋巴瘤相关研究进展进行综述.NK/T cell lymphoma(natural killer/T-cell lymphoma,NKTCL)is a rare and highly invasive subtype of non-Hodgkin lymphoma,which is closely associated with Epstein-Barr virus(EBV)infection,with a high incidence rate in Asia and Latin America.In recent years,the application of high-throughput sequencing technology has revealed the biological basis of NKTCL heterogeneity and the molecular pathogenic mechanisms,including the silencing of tumor suppressor gene caused by deletion of chromosome 6q21 allele,abnormal activation of several carcinogenic signal pathways due to EBV infection and somatic gene mutation,and abnormal epigenetic regulation.At present,there is no unified treatment standard for NKTCL.In the early stage,radiotherapy and chemotherapy are the main comprehensive treatment,while chemotherapy alone is the main option for the late stage.The prognosis of advanced and relapsed refractory patients is poor,and it is urgent to explore more effective treatment options.With the accelerated evolution of global new drug development,various new drugs against NKTCL are constantly emerging.This review summarizes the research progress in EBV-associated NK/T cell lymphoma.

关 键 词：NK/T细胞淋巴瘤 EB病毒 化疗 放疗 免疫治疗 

分 类 号：R733.1[医药卫生—肿瘤]